Loading
A phase 2 trial of JSB462 in prostate cancer, run by Novartis Pharmaceuticals, active and no longer recruiting.
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) is a phase 2 interventional study registered as NCT07047118 by Novartis Pharmaceuticals, with 138 participants enrolled, started 2025-07-03 and due to reach its primary completion in 2027-07-16. Interventions recorded: JSB462 and AAA617.
Shares Advanced Accelerator Applications (Novartis), Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.